Androgen receptor antagonists: A patent review (2008 - 2011)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 5, 2012, Pages 541-565

  Mohler, Michael L ^a   Coss, Christopher C ^a   Duke III, Charles B ^b   Patil, Shivaputra A ^b   Miller, Duane D ^b   Dalton, James T ^a  

^a GTx Inc   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Androgen receptor antagonist; Androgen receptor downregulating agent; Androgen receptor pan antagonist; Bicalutamide; Castration resistant prostate cancer; MDV3100; Noncompetitive androgen receptor antagonist; Nuclear translocation inhibitor; Selective androgen receptor degrader

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ABIRATERONE; ALPHA TOCOPHEROL DERIVATIVE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; BICALUTAMIDE; CURCUMIN; ESTROGEN RECEPTOR; FLUTAMIDE; GLUCOCORTICOID RECEPTOR; HYDROXYFLUTAMIDE; INDOLE DERIVATIVE; MINERALOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR; PROPIONAMIDE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SULFONAMIDE; THIOHYDANTOIN DERIVATIVE;

AMINO TERMINAL SEQUENCE; ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; DNA BINDING; DNA SEQUENCE; DNA STRUCTURE; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFICACY; DRUG INDUSTRY; DRUG STRUCTURE; DRUG SYNTHESIS; FETUS DEVELOPMENT; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HAIR GROWTH; IN VITRO STUDY; IN VIVO STUDY; OVARY CARCINOMA; OVARY POLYCYSTIC DISEASE; PATENT; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; SEX DIFFERENTIATION; SIGNAL TRANSDUCTION; XENOGRAFT;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LEGISLATION, DRUG; MALE; MOLECULAR STRUCTURE; MUTATION; PATENTS AS TOPIC; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84861493525     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.682571     Document Type: Review

References (131)

1. Lu NZ, Wardell SE, Burnstein KL, et al. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 2006;58:782-97
2. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86
3. Bennett NC, Gardiner RA, Hooper JD, et al. Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol 2010;42:813-27
4. Papadopoulou N, Papakonstanti EA, Kallergi G, et al. Membrane androgen receptor activation in prostate and breast tumor cells: molecular signaling and clinical impact. IUBMB Life 2009;61:56-61
5. Migliaccio A, Castoria G, Di Domenico M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. Embo J 2000;19:5406-17
6. Baron S, Manin M, Beaudoin C, et al. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 2004;279:14579-86
7. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175-200
8. Jenster G, van der Korput HA, van Vroonhoven C, et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991;5:1396-404
9. Choong CS, Wilson EM. Trinucleotide repeats in the human androgen receptor: a molecular basis for disease. J Mol Endocrinol 1998;21:235-57
10. van Royen ME, Cunha SM, Brink MC, et al. Compartmentalization of androgen receptor protein-protein interactions in living cells. J Cell Biol 2007;177:63-72
11. Schaufele F, Carbonell X, Guerbadot M, et al. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA 2005;102:9802-7
12. He B, Lee LW, Minges JT, Wilson EM. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J Biol Chem 2002;277:25631-9
13. Verrijdt G, Haelens A, Claessens F. Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 2003;78:175-85
14. Schoenmakers E, Alen P, Verrijdt G, et al. Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains. Biochem J 1999;341(Pt 3):515-21
15. Zhou ZX, Sar M, Simental JA, et al. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem 1994;269:13115-23
16. Clinckemalie L, Vanderschueren D, Boonen S, Claessens F. The hinge region in androgen receptor control. Mol Cell Endocrinol 2012
17. Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev 2005;105:3352-70
18. Lee DK, Chang C. Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 2003;88:4043-54
19. Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-13
20. Zhang X, Morrissey C, Sun S, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011;6:e27970
21. Neischlag E, Behre HM, Nieschlag S. Testosterone: Action, Deficiency, Substitution. Cambridge University Press; Cambridge, UK: 2004
22. Ruizeveld de Winter JA, Trapman J, Vermey M, et al. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 1991;39:927-36
23. Hershberger LG, Shipley EG, Meyer RK. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953;83:175-80
24. Freyberger A, Schladt L. Evaluation of the rodent Hershberger bioassay on intact juvenile males-testing of coded chemicals and supplementary biochemical investigations. Toxicology 2009;262:114-20
25. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004;25:389-425
26. Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 2004;7:271-7
27. De Gendt K, Verhoeven G. Tissue- and cell-specific functions of the androgen receptor revealed through conditional knockout models in mice. Mol Cell Endocrinol 2012;352:13-25
28. Matsumoto T, Shiina H, Kawano H, et al. Androgen receptor functions in male and female physiology. J Steroid Biochem Mol Biol 2008;109:236-41
29. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9-12
30. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29:3651-8
31. Basu S, Tindall DJ. Androgen action in prostate cancer. Horm Cancer 2010;1:223-8
32. Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci 2011;102:51-6
33. Papalia MA, Davis SR. What is the rationale for androgen therapy for women? Treat Endocrinol 2003;2:77-84
34. Beardsley EK, Chi KN. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2008;2:161-6
35. Osanto S, Van Poppel H. Emerging novel therapies for advanced prostate cancer. Ther Adv Urol 2012;4:3-12
36. Nadiminty N, Gao AC. Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol
37. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803-6
38. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8
39. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007;28:778-808
40. Matias PM, Carrondo MA, Coelho R, et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 2002;45:1439-46
41. Sramkoski RM, Pretlow TG II, Giaconia JM, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-9
42. Chlenski A, Nakashiro K, Ketels KV, et al. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001;47:66-75
43. Jamnongjit M, Hammes SR. Ovarian steroids: the good, the bad, and the signals that raise them. Cell Cycle 2006;5:1178-83
44. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219-31
45. Pache TD, Chadha S, Gooren LJ, et al. Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome? Histopathology 1991;19:445-52
46. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 1997;43:1262-79
47. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:241-9
48. Rittmaster RS. Antiandrogen treatment of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:409-21
49. Eagleson CA, Gingrich MB, Pastor CL, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-52
50. Franks S. Do animal models of polycystic ovary syndrome help to understand its pathogenesis and management? Yes, but their limitations should be recognized. Endocrinology 2009;150:3983-5
51. Li AJ, Karlan BY. Androgens and epithelial ovarian cancer: what's the connection? Cancer Biol Ther 2008;7:1712-16
52. Edmondson RJ, Monaghan JM, Davies BR. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 2002;86:879-85
53. Karlan BY, Jones J, Greenwald M, Lagasse LD. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol 1995;173:97-104
54. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. Jama 1995;274:1926-30
55. Schildkraut JM, Schwingl PJ, Bastos E, et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88:554-9
56. Cardillo MR, Petrangeli E, Aliotta N, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 1998;17:231-7
57. Chadha S, Rao BR, Slotman BJ, et al. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 1993;24:90-5
58. Li AJ, Baldwin RL, Karlan BY. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res 2003;9:3667-73
59. Tumolo S, Rao BR, van der Burg ME, et al. Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer 1994;30A:911-14
60. Levine D, Park K, Juretzka M, et al. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 2007;110:2448-56
61. Ligr M, Patwa RR, Daniels G, et al. Expression and function of androgen receptor coactivator p44/Mep50/ WDR77 in ovarian cancer. PLoS One 2011;6:e26250
62. Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res 2009;11:212
63. Rieche K, Wolff G. Comparison of testosterone decanoate, drostanolone and testololactone in disseminated breast cancer-a randomized clinical study. Arch Geschwulstforsch 1975;45:485-8
64. Bicalutamide in Treating Patients With Metastatic Breast Cancer Trial#NCT00468715. Memorial Sloan-Kettering Cancer Center 2011. Available from: http://clinicaltrials.gov/ show/NCT00468715
65. Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer celllines. J Steroid Biochem Mol Biol 1995;52:459-67
66. Giguere Y, Dewailly E, Brisson J, et al. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res 2001;61:5869-74
67. Bulbrook RD, Thomas BS, Utsunomiya J, Hamaguchi E. The urinary excretion of 11-deoxy-17- oxosteroids and 17-hydroxycorticosteroids by normal Japanese and British women. J Endocrinol 1967;38:401-6
68. Tamimi RM, Hankinson SE, Chen WY, et al. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166:1483-9
69. Tworoger SS, Missmer SA, Eliassen AH, et al. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev 2006;15:967-71
70. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 1998;3:95-103
71. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am 1997;24:421-31
72. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21:2673-8
73. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9
74. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65
75. Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010;107:16759-65
76. Diarylhydantoin compounds. 2006;WO06124118
77. Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases. 2007;WO07126765
78. Clegg NJ, Wongvipat J, Tran C, et al. ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer Res 2012;72:1494-1503 . Clegg et al. discuss the preclinical data for ARN-509 (2).
79. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90
80. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46
81. Imidazolidines substituted with a heterocycle. US5705654
82. Diaryl hydantoin compounds. WO09055053
83. Synthesis of thiohydantoins. WO08119015
84. Androgen receptor modulators and uses thereof. WO11103202 2011
85. Androgen receptor inactivation contributes to anti-tumor efficacy of CYP17 (lyase) inhibitors in prostate cancer. WO09114658 2009
86. Novel prodrugs of C-17 heteroaryl steroidal CYP17 inhibitors/ anitandrogens: Synthesis, in vitro biological activities, pharmacokinetics and antitumor activity. W009120565
87. Novel prodrugs of steroidal CYP17 inhibitors/anti-androgens. WO10091306
88. Bicyclic derivatives for use in the treatment of androgen receptor associated conditions. WO09081197
89. Amide derivatives. WO08044033
90. Thiazole derivatives as androgen receptor modulator compounds. WO08124000
91. Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss. WO09017815
92. Compounds with anti-androgenic activity and the use thereof. WO08060949
93. Methods for treating androgen receptor related disorders. US080015207
94. Anticancer agents and androgen inhibition activity compound. WO08076918
95. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992;89:6319-23
96. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004;91:483-90
97. Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal. US2010331418
98. McGinley PL, Koh JT. Circumventing anti-androgen resistance by molecular design. J Am Chem Soc 2007;129:3822-3
99. Pan-Antagonists of the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal. WO08013791
100. Substituted pyrrolidine derivative and use thereof. WO09131196
101. Substituted pyrazole derivative. WO09028543
102. Substituted yrazole derivatives and uses thereof. WO09119880
103. Androgen receptor modulating compounds, preparation and uses thereof. WO10092546
104. Non-steroidal compounds for androgen receptor modulation. WO10116342
105. Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function. WO09003077
106. Fused heterocyclic compounds useful as modulators of NHR function. WO09059077
107. 17alpha-Substituted steroidal as systemic antiandrogens and selective androgen receptor modulators. WO08124922
108. Androgen receptor antagonists and uses thereof. WO11029392
109. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostatecancer. Proc Natl Acad Sci USA 2007;104:1331-6
110. Moore TW, Mayne CG, Katzenellenbogen JA. Minireview: not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 2010;24:683-95
111. Chang CY, McDonnell DP. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 2005;26:225-8
112. Gunther JR, Parent AA, Katzenellenbogen JA. Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem Biol 2009;4:435-40
113. Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNAbinding polyamide. Proc Natl Acad Sci USA 2007;104:10418-23
114. Chenoweth DM, Harki DA, Phillips JW, et al. Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J Am Chem Soc 2009;131:7182-8
115. Diglycidic ether derivative therapeutics and their methods of use. WO10000066
116. Andersen RJ, Mawji NR, Wang J, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010;17:535-46
117. Bisphenol derivations and their use as androgen receptor activity modulators. WO11082487
118. Bisphenol derivative therapeutics and methods for their use. WO11082488
119. Oligo-benzamide compounds and their use. W011150360
120. Wittmann BM, Sherk A, McDonnell DP. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res 2007;67:9549-60
121. Small-molecule inhibitors of the androgen receptor. WO08128100
122. Haendler B, Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Mol Cell Endocrinol 2012;352:79-91
123. Wijayaratne AL, McDonnell DP. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001;276:35684-92
124. Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor alpha by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol 2010;82:122-30
125. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-70
126. Robertson JF. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 2007;12:774-84
127. Denmeade SR, Sokoll LJ, Dalrymple S, et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003;54:249-57
128. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-40
129. Buchanan G, Birrell SN, Peters AA, et al. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res 2005;65:8487-96
130. Minesita T, Yamaguchi K, Yahara I, Matsumoto K. Incorporation of radioactivity following administration of testosterone-3H in the androgen dependent mouse tumor, Shionogi carcinoma 115. Steroids 1970;15:751-63
131. Subik K, Lee JF, Baxter L, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl) 4:35-41